Enzene Targets Local Biomanufacturing with New Solutions
NeX, which is built on the EnzeneX continuous manufacturing (FCCM) platform, is designed to deliver a turnkey and scalable way to make biologics manufacturing transportable, close to patients and supply chains. The post Enzene Targets Local Biomanufacturing with New Solutions appeared first on GEN - Genetic Engineering and Biotechnology News .
CDMO Enzene has unveiled NeX, a comprehensive partnership model that facilitates the establishment of advanced biomanufacturing infrastructure in various locations. This innovative platform, based on the EnzeneX continuous manufacturing system (FCCM), aims to provide a cost-effective and scalable solution for biologics production.
Enzene's CEO, Himanshu Gadgil, highlights the significant cost savings that can be achieved through this compact, integrated system design. Unlike traditional biologics plants that can cost between $300 million and $400 million to build, NeX enables the same output at a much lower price range of $60–$80 million. This approach not only reduces capital expenditure but also offers long-term cost advantages and high product yields.
Gadgil emphasizes that NeX helps regions expedite the development of local biopharma capabilities, strengthens supply chains, and enhances domestic scientific talent, while simultaneously lowering long-term manufacturing costs for local patients. According to Enzene, facilities under the NeX program can achieve validation and commercial readiness within a timeframe of less than three years.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
